NCT04697654View on ClinicalTrials.gov

The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 8, 2020

Primary Completion Date

June 18, 2021

Study Completion Date

June 18, 2021

Conditions
COVID-19
Interventions
DRUG

TLC19

Hydroxychloroquine Liposome Inhalation Suspension

DRUG

TLC19 Vehicle

Liposome Inhalation Suspension (same formulation as TLC19 but without the active ingredient, HCQ)

Trial Locations (1)

10449

Mackay Memorial Hospital Tamsui Branch, Taipei

Sponsors
All Listed Sponsors
lead

Taiwan Liposome Company

INDUSTRY